San Francisco biotech developing drugs that activate iNKT immune cells to clear senescent cells from the body.
Seattle biotech using a non-viral lipid delivery platform to deliver gene-directed payloads that destroy senescent cells.
Join to open the full comparison.
You'll get The Briefing by email. Unsubscribe in one click. Terms · Privacy
The Briefing, free for life.